Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.60 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.60 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.60 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 4/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL20529828 | 0.94 | P2RY1 (0.65) | FBP1ADORA1SMN1; SMN2RNASEL | |
| SCHEMBL20529826 | 0.90 | P2RY1 (0.65) | FBP1ADORA1SMN1; SMN2RNASEL | |
| Adenosine Phosphate SCHEMBL31666008 | 0.90 | P2RY1 (0.69) | FBP1ADORA1SMN1; SMN2RNASEL | |
| SCHEMBL5924576 | 0.89 | FBP1 (0.72) | FBP1SLC28A2HSPA8HSPA5RXFP1 | |
| SCHEMBL5924577 | 0.89 | FBP1 (0.72) | FBP1SLC28A2HSPA8HSPA5RXFP1 | |
| SCHEMBL8388000 | 0.83 | FBP1 (0.64) | FBP1ADORA1SMN1; SMN2 | |
| SCHEMBL20266254 | 0.83 | FBP1 (0.63) | FBP1ADORA1SMN1; SMN2 | |
| Adenosine SCHEMBL9147194 | 0.82 | ADORA1 (0.89) | FBP1SLC28A2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL459769 | 0.82 | ADORA1 (0.89) | FBP1SLC28A2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL6242700 | 0.82 | ADORA1 (0.89) | FBP1SLC28A2DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | AVIDEA TECHNOLOGIES, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3606551-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | Avidea Technologies, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018187515-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | AVIDEA TECHNOLOGIES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | MYD88, ICOS, CD4 | ADORA3 4678/4885ADORA2A 4805/4885ADORA2B 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.